Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results
The blood levels of nasal sprays can vary and are generally lower compared to injectable peptides
This is the kind of breakdown we use internally when advising research partners
All 32 participants completed the study
It helps orchestrate healing at the cellular level, particularly after injury
Medical detox and treatment programs focus on: Stabilizing the body safely Managing withdrawal symptoms with oversight Supporting sleep, nutrition, and mental health Medications like: Buprenorphine Methadone Naltrexone Have strong evidence showing they: Reduce cravings Lower overdose risk Improve long-term outcomes Sleep and stress, which DSIP targets, are also addressed through: Structured care Therapy Medication when appropriate Routine and stabilization A Better Way to Look at It DSIP is interesting from a research perspective
